Large vaccine trials that are extensive both in size and scope tax the resources of sponsors and contract research organizations (CROs), particularly when the trials seek to compress a process that ordinarily takes years. Rapid but safe implementation of these vaccine studies’ new protocols is pushing trial design to the limit.